title: Assessment of local cellular immunity in lung cancer by bronchoalveolar lavage.
abstract: Small cell lung cancer (SCLC) is the most malignant of the pulmonary neoplasms and is associated with a poor local cellular immune response. 16 patients with non small cell lung cancer (NSCLC) and 11 patients with SCLC underwent bronchoalveolar lavage (BAL) in the lung which harbored the tumor in order to investigate the lymphocyte surface antigens utilizing the immunoperoxidase technique. Analysis of blood lymphocytes was performed in parallel. 8 patients with previous sarcoidosis in complete remission who underwent BAL and 10 normal blood donors served as controls. Among blood lymphocytes the CD3+, CD4+ and CD16+ cell populations were elevated significantly and the T4/T8 ratio was elevated in NSCLC patients, but only CD16+ were augmented in SCLC. Cell populations expressing the activation markers transferrin (TF) receptor, interleukin-2 (IL-2) receptor and the very late antigen VAL-1 were also increased in NSCLC, while SCLC was associated with antigen distributions similar to controls. No differences between the cohorts were seen in the expression of human leukocyte antigen (HLA)-DR. In BAL the population of CD3+ and CD4+ cells were reduced in SCLC and the T4/T8 ratio was diminished in contrast to controls and NSCLC patients, whereas these two latter groups did not differ from each other. The distribution pattern of CD16, TF receptor and IL-2 receptor in the study groups resembled that of cells of the blood stream, but CD16+ natural killer cells were additionally down regulated to control values in SCLC. No differences were seen in the distribution of VLA-1. HLA-DR+ cells were clearly elevated in both cancer groups.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: III. Medizinische Klinik mit Schwerpunkt Pneumologie Klinikum, Johannes Gutenberg-Universität Mainz.
authors.forename: J
authors.initials: J
authors.lastname: Lorenz
authors.forename: J
authors.initials: J
authors.lastname: Müller-Quernheim
authors.forename: C
authors.initials: C
authors.lastname: Castillo-Höfer
authors.forename: A
authors.initials: A
authors.lastname: Doboszỳnska
authors.forename: R
authors.initials: R
authors.lastname: Ferlinz
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology; D015703:Antigens, CD / Q000032:analysis; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology*; D018288:Carcinoma, Small Cell / Q000276:immunology*; D002294:Carcinoma, Squamous Cell / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology; D007958:Leukocyte Count; D008175:Lung Neoplasms / Q000276:immunology*; D015375:Receptors, Interleukin-2 / Q000032:analysis; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D015703:Antigens, CD; D015375:Receptors, Interleukin-2